ARTICLE | Company News
Cell Cure Neurosciences, Teva deal
October 25, 2010 7:00 AM UTC
Cell Cure, a majority-owned subsidiary of BioTime Inc. (NYSE-A:BTX), granted Teva an exclusive option to license exclusive, worldwide rights to develop and commercialize Cell Cure's OpRegen to treat...